Form 4: Astria Therapeutics CEO Jill C. Milne Granted Stock Options

Astria Therapeutics CEO Jill C. Milne was granted stock options for 761,000 shares on March 21, 2025, according to a Form 4 filing.

Summary

• Jill C. Milne, CEO and President of Astria Therapeutics, Inc., received stock options on March 21, 2025.
• The options grant covers 761,000 shares of Astria Therapeutics common stock.
• The exercise price of the stock options is $6.41.
• The options vest over a four-year period, starting with 25% vesting on the first anniversary of February 13, 2025, and the remainder vesting in equal monthly installments over the following three years.
• The options expire on March 20, 2035.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing related to executive compensation. It is neutral in tone and does not contain any information that would significantly impact investor sentiment positively or negatively.

Positives

• The grant of stock options to the CEO aligns her interests with those of the shareholders.
• The vesting schedule incentivizes long-term performance and commitment from the CEO.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. The size and vesting schedule of the grant are typical for a company of Astria Therapeutics' size and stage of development.

Comparison to Industry Standards

• Stock option grants to CEOs in the biotech industry typically range from 1x to 5x their base salary, depending on the company's size, stage, and performance.
• Vesting schedules are usually over a 3to 5-year period, with a cliff vesting of 25% to 33% after the first year, followed by monthly or quarterly vesting for the remaining shares.
• Comparable companies like BioCryst Pharmaceuticals or Sarepta Therapeutics also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant aligns the CEO's interests with those of shareholders, potentially leading to increased shareholder value.
• The grant could motivate the CEO to drive company performance, benefiting employees and other stakeholders.

Key Dates

Keywords

stock options, Astria Therapeutics, ATXS, CEO, Jill C. Milne, Form 4, executive compensation, equity